Last Updated on November 23, 2022 by GlobeNewsWire
NEWARK, Calif., Nov. 23, 2022 (GLOBE NEWSWIRE) — Rain Therapeutics Inc. (NasdaqGS: RAIN), (Rain), a late-stage biotechnology company developing precision oncology therapeutics with a lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates p53, today announced a poster presentation at the upcoming 2022 San Antonio Breast Cancer Symposium (SABCS) taking place on December 6-10, 2022 in San Antonio, TX.
Presentation Title:Genetic alterations in breast cancer associated with MDM2 dependency and sensitivity to the MDM2 inhibitor milademetanAuthors:Francois-Clement Bidard, Diana Bello Roufai, Arielle J. Medford, Vijaya Tirunagaru, Robert C. Doebele, Aditya BardiaPoster Session / Category:Session 6 / Treatment: Therapeutic Strategies – Novel Targets and Targeted AgentsPoster Number:P6-10-10Session Date and Time:Friday, December 9, 2022; 7:00 AM CTLocation:Henry B. Gonzalez Convention Center, Hall 1
A copy of the presentation materials can be accessed by visiting the “Resources” section of the Rain website after the conclusion of the presentation and will be archived on the Rain website.
About Rain Therapeutics Inc.Rain Therapeutics Inc. is a late-stage precision oncology company developing therapies that target oncogenic drivers to genetically select patients it believes will most likely benefit. This approach includes using a tumor-agnostic strategy to select patients based on their tumors’ underlying genetics rather than histology. Rain’s lead product candidate, milademetan, is a small molecule, oral inhibitor of MDM2-p53 complex that reactivates p53. In addition to milademetan, Rain is also developing a preclinical program that is focused on inducing synthetic lethality in cancer cells by inhibiting RAD52.
Investor ContactDan FerryLifeSci Advisors+1.617.430.7576daniel@lifesciadvisors.com
Media Contact Jordyn Temperato LifeSci Communications jtemperato@lifescicomms.com
Leave a Reply